137 related articles for article (PubMed ID: 7993844)
1. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
Dirix LY; van Meerbeeck J; Schrijvers D; Corthouts B; Prové A; van Marck E; Vermeire P; van Oosterom AT
Ann Oncol; 1994 Sep; 5(7):653-5. PubMed ID: 7993844
[TBL] [Abstract][Full Text] [Related]
2. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
3. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
Zidar BL; Metch B; Balcerzak SP; Pierce HI; Militello L; Keppen MD; Berenberg JL
Cancer; 1992 Nov; 70(10):2547-51. PubMed ID: 1423183
[TBL] [Abstract][Full Text] [Related]
4. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
Leyvraz S; Bacchi M; Cerny T; Lissoni A; Sessa C; Bressoud A; Hermann R
Ann Oncol; 1998 Aug; 9(8):877-84. PubMed ID: 9789611
[TBL] [Abstract][Full Text] [Related]
5. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
Falkson G; Hunt M; Borden EC; Hayes JA; Falkson CI; Smith TJ
Invest New Drugs; 1992 Nov; 10(4):337-43. PubMed ID: 1487409
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
Steward WP; Verweij J; Somers R; Blackledge G; Clavel M; Van Oosterom AT; Greifenberg B; Soedirman J; Thomas D; Van Glabbeke M
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S193-7. PubMed ID: 1795008
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Steward WP; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E
J Clin Oncol; 1993 Jan; 11(1):15-21. PubMed ID: 8418226
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
10. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
Pennucci MC; Ardizzoni A; Pronzato P; Fioretti M; Lanfranco C; Verna A; Giorgi G; Vigani A; Frola C; Rosso R
Cancer; 1997 May; 79(10):1897-902. PubMed ID: 9149015
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma.
Carmichael J; Cantwell BM; Harris AL
Eur J Cancer Clin Oncol; 1989 May; 25(5):911-2. PubMed ID: 2500344
[No Abstract] [Full Text] [Related]
13. Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.
Planting AS; de Wit R; van der Burg ME; Stoter G; Verweij J
Ann Oncol; 1996 Dec; 7(10):1080-2. PubMed ID: 9037369
[TBL] [Abstract][Full Text] [Related]
14. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
Toma S; Palumbo R; Comandone A; Oliva C; Vincenti M; Bumma C; Rosso R
Ann Oncol; 1995 Feb; 6(2):193-6. PubMed ID: 7540421
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
Schütte J; Mouridsen HT; Stewart W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
Eur J Cancer; 1990; 26(5):558-61. PubMed ID: 2144740
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Bokemeyer C; Franzke A; Hartmann JT; Schöber C; Arseniev L; Metzner B; Link H; Kanz L; Schmoll HJ
Cancer; 1997 Oct; 80(7):1221-7. PubMed ID: 9317171
[TBL] [Abstract][Full Text] [Related]
18. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
Skubitz KM; Hamdan H; Thompson RC
Cancer; 1993 Nov; 72(10):2963-9. PubMed ID: 8221562
[TBL] [Abstract][Full Text] [Related]
19. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]